Security
First Tracks Biotherapeutics, Inc. · TRAX
TRAXNASDAQCommon stockCurrentCIK 2091349Updated Oct 14, 2026
Name history
Biopharma Company, Inc. · through Feb 6, 2026
TRAX price & chart
Loading TradingView…
NASDAQ:TRAX on TradingView ↗About the company
We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Our clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which we completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (“RA”), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (“CeD”) and eosinophilic esophagitis (“EoE”), and ANB101, a BDCA2 modulator, in a Phase 1a trial.
In the news
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
4 filing
4 filing
SCHEDULE 13G filing
Show 5 more recent filings
Offerings
Registration 333-295719
Filing attachments
trax-ex99_2.htm · 8-K · 2026-10-13
Exhibit 99.2 First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease • ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms • LS mean change from baseline in Vh:Cd ratio of -0.17 on ANB033 vs. -0.66 on placebo, a +0.49 placebo-adjusted delta (p=0.009) • LS mean change from baseline in IEL density of -1.20 on ANB033 vs. +18.83 on placebo, a -…
Read attachment ↗trax-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 trax-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update • Completed enrollment for Cohort 1 (gluten challenge) of Phase 1b ANB033 trial in celiac disease (CeD); top-line Cohort 1 data reaffirmed for Q4 2026 • Cohort 2 (mucosal healing) enhanced to enroll up to 40 patients including those with a broad range of histologic (Vh:Cd ratio ≤ 2.5) and symptom severity to further inform future…
Read attachment ↗trax-ex99_1.htm · 8-K · 2026-05-14
EX-99.1 2 trax-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update • First Tracks launched April 20th with a two-year cash-runway to advance ANB033 through celiac disease and eosinophilic esophagitis Phase 1b data and plans to initiate Phase 2 trials across four indications SAN DIEGO, CA - May 14, 2026 - First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company adv…
Read attachment ↗d53570dex107.htm · S-1 · 2026-05-08
Exhibit 10.7 FIRST TRACKS BIOTHERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED STOCK UNIT AWARD You (“Participant”) have been granted an award of Restricted Stock Units (“RSUs”) under the First Tracks Biotherapeutics, Inc. (the “Company”) 2026 Equity Incentive Plan (the “Plan”), subject to the terms and conditions of the Plan, this Notice of Restricted Stock Unit Award (the “Notice”) and the attached Restricted Stock Unit Award Agreement, the (“Agreement”). Unless otherwise…
Read attachment ↗d78703dex991.htm · 8-K · 2026-04-20
EX-99.1 7 d78703dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, CA - April 20, 2026 - First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX) today announced its launch as an independent, publicly traded clinical-stage biotechnology company advancing antibody therapeuti…
Read attachment ↗